Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: National Nutritional Foods Association

This article was originally published in The Tan Sheet

Executive Summary

National Nutritional Foods Association: Submits June 10 comments on FDA's Dec. 28 proposed implementation of regs for DSHEA ("The Tan Sheet", Jan. 1, p. 2) representing "the best possible consensus among NNFA and the other trade associations," the group says. Key points mirror those made by the Council for Responsible Nutrition and the Nonprescription Drug Manufacturers Association ("The Tan Sheet" April 15, pp. 11-12): the term "Dietary Supplement" does not need to appear on principal display panels; boxing the DSHEA disclaimer is unnecessary; multiple disclaimers are unnecessary; "Supplement Facts" is a more appropriate heading than "Nutrition Facts" for supplement labels; and at least 18 months from the date of publication will be needed to comply with the regs...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel